
Please try another search
Biohaven Ltd. is a clinical-stage biopharmaceutical company. The Company combines a deep understanding of neuroscience, immunology, disease-related biology, advanced chemistry, and expertise in global clinical trials to advance novel therapies for patients. The Company is engaged in delivering new drug approvals for products for diseases such as migraine and schizophrenia, and its research programs, built on a deep understanding of disease-related biology and neuropharmacology, are advancing novel therapies with indications in spinocerebellar ataxia (SCA), amyotrophic lateral sclerosis (ALS), spinal muscular atrophy (SMA), epilepsy, depression, obsessive-compulsive disorder (OCD) and neuropathic pain. Its Neuroinnovation portfolio includes a broad pipeline of drug candidates modulating distinct nervous system targets, including Kv7 ion channels (Kv7), glutamate receptors, myeloperoxidase (MPO), myostatin, and transient receptor potential (TRP) channels.
Name | Age | Since | Title |
---|---|---|---|
Gerard Sanacora | - | - | Member of Scientific Advisory Board |
John Winston Childs | 81 | 2022 | Independent Director |
Robert J. Hugin | 68 | 2022 | Independent Director |
Kishan Mehta | 36 | 2022 | Director |
Gregory H. Bailey | 67 | 2022 | Independent Director |
Irina Antonijevic | 58 | 2022 | Independent Director |
John H. Krystal | - | - | Member of Scientific Advisory Board |
Richard B. Lipton | - | - | Member of Scientific Advisory Board |
Vladimir Coric | 52 | 2022 | Chairman & CEO |
Julia Paige Gregory | 71 | 2022 | Independent Director |
Michael Thomas Heffernan | 59 | 2022 | Lead Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review